Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial

被引：0
|
作者：
Jotte, R. [1 ]
Conkling, P. R. [2 ]
Reynolds, C. [3 ]
Shah, C. [4 ]
Galsky, M. [5 ]
Klein, L.
Fitzgibbons, J. F. [6 ]
McNally, R. [7 ]
Oliver, J. W. [8 ]
Renschler, M. [8 ]
机构：
[1] Rocky Mt Canc Ctr US Oncol, Denver, CO USA
[2] Virginia Oncol Associates US Oncol, Norfolk, VA USA
[3] Ocala Oncol Ctr US Oncol, Ocala, FL USA
[4] SUNY Upstate Med Univ, Syracuse, NY USA
[5] Nevada US Oncol, Ctr Comprehens Canc, Las Vegas, NV USA
[6] Sacred Heart Med Ctr US Oncol, Spokane, WA USA
[7] Celgene Corp, Biostat, Summit, NJ USA
[8] Celgene Corp, Clin Dev, Summit, NJ USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71833-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：540 / 541
页数：2
相关论文
共 50 条
  • [1] Second-line amrubicin (AMR) vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum based chemotherapy: updated results of a randomized phase 2 trial
    Jotte, Robert M.
    Conkling, Paul
    Reynolds, Craig
    Shah, Chirag
    Galsky, Matthew D.
    Klein, Leonard
    Fitzgibbons, James F.
    McNally, Richard
    Renschler, Markus
    Oliver, Jennifer W.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S399 - S399
  • [2] AMRUBICIN (AMR) VS TOPOTECAN AS SECOND-LINE TREATMENT OF EXTENSIVE-DISEASE SMALL CELL LUNG CANCER (SCLC) SENSITIVE TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY: A RANDOMIZED PHASE 2 TRIAL
    Jotte, R. M.
    Reynolds, C.
    Conkling, P.
    Jungnelius, U.
    Oliver, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 116 - 116
  • [3] Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy
    Jotte, R.
    Conkling, P.
    Reynolds, C.
    Klein, L.
    Fitzgibbons, J. F.
    McNally, R.
    Renschler, M.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
    Jotte, R. M.
    Conkling, P. R.
    Reynolds, C.
    Allen, A. R.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A randomized phase 2 trial of amrubicin compared to topotecan as second-line treatments in extensive disease small cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
    Jotte, R. M.
    Reynolds, C. H.
    Conkling, P.
    Oliver, J. W.
    Allen, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: updated results of a phase 2 trial
    Ettinger, David S.
    Jotte, Robert M.
    Paul, Lorigan
    Gupta, Vicram
    Garbo, Lawrence
    Alemany, Carlos
    Spigel, David R.
    Dudek, Arkadiusz Z.
    Salgia, Ravi
    McNally, Richard
    Renschler, Markus
    Oliver, Jennifer W.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S398 - S399
  • [7] Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial
    Ettinger, D. S.
    Jotte, R.
    Lorigan, P.
    Gupta, V.
    Garbo, L.
    Spigel, D.
    Dudek, A. Z.
    Salgia, R.
    McNally, R.
    Renschler, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 541 - 541
  • [8] Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update
    Ettinger, D. S.
    Jotte, R.
    Lorigan, P.
    Gupta, V.
    Garbo, L.
    Conkling, P.
    Spigel, D.
    McNally, R.
    Renschler, M.
    Oliver, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
    Jotte, Robert
    Conkling, Paul
    Reynolds, Craig
    Galsky, Matthew D.
    Klein, Leonard
    Fitzgibbons, James F.
    McNally, Richard
    Renschler, Markus F.
    Oliver, Jennifer W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) : 287 - 293
  • [10] CARDIAC SAFETY OF AMRUBICIN IN A RANDOMIZED PHASE 3 TRIAL OF AMRUBICIN VS TOPOTECAN AS SECOND-LINE TREATMENT FOR SMALL CELL LUNG CANCER (SCLC)
    Spigel, David R.
    Von Pawel, Joachim
    Jotte, Robert
    Socinski, Mark A.
    O'Brien, Mary E. R.
    Mcnally, Richard
    Renschler, Markus
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S309 - S309
12345